SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- obesity/erectile dysfunction
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: scaram(o)uche9/4/2013 1:57:30 PM
   of 435
 
Br J Pharmacol. 2013 Aug 28. doi: 10.1111/bph.12360. [Epub ahead of print]

Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (Suncus murinus).

O'Brien LD, Limebeer CL, Rock EM, Bottegoni G, Piomelli D, Parker LA.

Department of Psychology and Collaborative Neuroscience Program University of Guelph, Guelph, ON, Canada.

BACKGROUND AND PURPOSE:

To understand how anandamide transport inhibition impacts the regulation of nausea and vomiting and the receptor level mechanism of action involved. In light of recent characterization of an anandamide transporter, FAAH-1-like anandamide transporter (FLAT), to provide behavioral support for anandamide cellular reuptake as a facilitated transport process.

EXPERIMENTAL APPROACH:

The systemic administration of the anandamide transport inhibitor ARN272 was used to evaluate the prevention of LiCl-induced nausea-induced behaviour (conditioned gaping) in rats, and LiCl-induced emesis in shrews (Suncus murinus). The mechanism of how prolonging anandamide availability acts to regulate nausea in rats was explored by the antagonism of CB1 receptors with the systemic co-administration of SR141716.

KEY RESULTS:

The systemic administration of ARN272 produced a dose-dependent suppression of nausea-induced conditioned gaping in rats, and produced a dose-dependent reduction of vomiting in shrews. The systemic co-administration of SR141716 with ARN272 (at 3.0 mg.kg-1 ) in rats produced a complete reversal of ARN272-suppressed gaping at 1.0 mg.kg-1 . SR141716 alone did not differ from VEH.

CONCLUSIONS AND IMPLICATIONS:

These results suggest that anandamide transport inhibition by the compound ARN272 tonically activates CB1 receptors and as such produces a type of indirect agonism to regulate toxin-induced nausea and vomiting. The results also provide behavioral evidence in support of a facilitated transport mechanism used in the cellular reuptake of anandamide
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News